| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 98 | 2023 | 354 | 22.520 |
Why?
|
| Infant | 59 | 2022 | 2929 | 2.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2022 | 2346 | 2.270 |
Why?
|
| Child, Preschool | 51 | 2021 | 3524 | 2.040 |
Why?
|
| N-Myc Proto-Oncogene Protein | 19 | 2022 | 34 | 2.030 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 124 | 2.010 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 3 | 2020 | 4 | 1.900 |
Why?
|
| HIV Infections | 10 | 2022 | 667 | 1.760 |
Why?
|
| Child | 55 | 2022 | 6544 | 1.660 |
Why?
|
| 3-Iodobenzylguanidine | 8 | 2022 | 19 | 1.540 |
Why?
|
| Disease-Free Survival | 23 | 2022 | 1183 | 1.410 |
Why?
|
| Gene Amplification | 10 | 2021 | 129 | 1.390 |
Why?
|
| Induction Chemotherapy | 5 | 2022 | 144 | 1.370 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2021 | 1219 | 1.340 |
Why?
|
| Prognosis | 32 | 2022 | 3544 | 1.270 |
Why?
|
| Oncogene Proteins | 13 | 2015 | 58 | 1.230 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1409 | 1.170 |
Why?
|
| Humans | 113 | 2023 | 80897 | 1.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 680 | 1.010 |
Why?
|
| Pelvic Neoplasms | 3 | 2014 | 42 | 0.990 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 78 | 0.990 |
Why?
|
| Antineoplastic Agents | 13 | 2016 | 2274 | 0.980 |
Why?
|
| 5-Methylcytosine | 3 | 2022 | 101 | 0.970 |
Why?
|
| Neoplasm Staging | 22 | 2021 | 1883 | 0.950 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 1363 | 0.930 |
Why?
|
| Immunotherapy | 8 | 2021 | 570 | 0.920 |
Why?
|
| Nuclear Proteins | 13 | 2015 | 682 | 0.890 |
Why?
|
| HIV-1 | 3 | 2021 | 135 | 0.890 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2022 | 1163 | 0.890 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 247 | 0.870 |
Why?
|
| Cell Proliferation | 5 | 2019 | 1539 | 0.840 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 61 | 0.840 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 56 | 0.840 |
Why?
|
| Chromosome Aberrations | 6 | 2020 | 381 | 0.810 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 10 | 0.800 |
Why?
|
| Female | 59 | 2022 | 42456 | 0.790 |
Why?
|
| Adolescent | 34 | 2021 | 8669 | 0.780 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 87 | 0.780 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 843 | 0.780 |
Why?
|
| DNA Methylation | 4 | 2022 | 590 | 0.770 |
Why?
|
| Stem Cell Transplantation | 8 | 2019 | 176 | 0.740 |
Why?
|
| Epigenomics | 1 | 2019 | 86 | 0.730 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 68 | 0.710 |
Why?
|
| Naphthyridines | 1 | 2019 | 50 | 0.690 |
Why?
|
| Male | 48 | 2021 | 39412 | 0.670 |
Why?
|
| Infant, Newborn | 14 | 2021 | 2273 | 0.670 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 152 | 0.660 |
Why?
|
| Risk Factors | 19 | 2021 | 5137 | 0.660 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 274 | 0.640 |
Why?
|
| Prednisone | 1 | 2017 | 252 | 0.630 |
Why?
|
| Cell Line, Tumor | 12 | 2022 | 2324 | 0.630 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.620 |
Why?
|
| Palmitic Acid | 1 | 2016 | 26 | 0.620 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.620 |
Why?
|
| Survival Rate | 14 | 2021 | 1811 | 0.610 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 1613 | 0.610 |
Why?
|
| Tissue Fixation | 1 | 2016 | 39 | 0.590 |
Why?
|
| Medical Oncology | 3 | 2021 | 331 | 0.590 |
Why?
|
| Isotretinoin | 3 | 2021 | 23 | 0.590 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 77 | 0.590 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.590 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 842 | 0.570 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 188 | 0.560 |
Why?
|
| Altruism | 1 | 2015 | 34 | 0.560 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 336 | 0.540 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 3533 | 0.520 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 2192 | 0.520 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2017 | 76 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 258 | 0.500 |
Why?
|
| Genomics | 3 | 2021 | 650 | 0.490 |
Why?
|
| Radiation Injuries | 1 | 2014 | 154 | 0.490 |
Why?
|
| Risk Assessment | 10 | 2020 | 2171 | 0.480 |
Why?
|
| Cohort Studies | 13 | 2021 | 2583 | 0.480 |
Why?
|
| Treatment Outcome | 14 | 2022 | 7492 | 0.470 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2020 | 17 | 0.470 |
Why?
|
| Salvage Therapy | 4 | 2021 | 227 | 0.470 |
Why?
|
| Hypoxia | 2 | 2022 | 605 | 0.460 |
Why?
|
| Radiotherapy | 1 | 2014 | 324 | 0.460 |
Why?
|
| Young Adult | 16 | 2021 | 5725 | 0.460 |
Why?
|
| Pediatrics | 2 | 2021 | 336 | 0.460 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2020 | 67 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 561 | 0.440 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 176 | 0.430 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 63 | 0.430 |
Why?
|
| Prospective Studies | 10 | 2022 | 3926 | 0.430 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 11 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2303 | 0.420 |
Why?
|
| Age Factors | 11 | 2021 | 1778 | 0.420 |
Why?
|
| Algorithms | 1 | 2019 | 1776 | 0.410 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 188 | 0.410 |
Why?
|
| Iodine Radioisotopes | 4 | 2022 | 120 | 0.410 |
Why?
|
| Quinoxalines | 1 | 2011 | 49 | 0.410 |
Why?
|
| Pyridines | 2 | 2012 | 299 | 0.400 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 1036 | 0.390 |
Why?
|
| Recurrence | 5 | 2023 | 1118 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 291 | 0.370 |
Why?
|
| International Cooperation | 3 | 2020 | 124 | 0.360 |
Why?
|
| Biomedical Research | 3 | 2021 | 349 | 0.350 |
Why?
|
| Health Status Disparities | 1 | 2010 | 155 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 558 | 0.350 |
Why?
|
| Parents | 2 | 2022 | 255 | 0.330 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 917 | 0.330 |
Why?
|
| United States | 6 | 2021 | 6169 | 0.330 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 824 | 0.320 |
Why?
|
| Interleukin-2 | 3 | 2021 | 240 | 0.320 |
Why?
|
| Survivors | 3 | 2022 | 209 | 0.320 |
Why?
|
| Adult | 22 | 2021 | 24636 | 0.310 |
Why?
|
| Disease Progression | 5 | 2014 | 1435 | 0.300 |
Why?
|
| Ganglioneuroblastoma | 2 | 2018 | 4 | 0.290 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1328 | 0.280 |
Why?
|
| Risk | 4 | 2019 | 667 | 0.280 |
Why?
|
| Time Factors | 6 | 2019 | 5094 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 646 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2020 | 105 | 0.260 |
Why?
|
| Mixed Function Oxygenases | 2 | 2022 | 68 | 0.260 |
Why?
|
| Genome-Wide Association Study | 3 | 2017 | 1534 | 0.250 |
Why?
|
| Gangliosides | 2 | 2016 | 10 | 0.250 |
Why?
|
| Thoracic Neoplasms | 2 | 2014 | 60 | 0.250 |
Why?
|
| Radionuclide Imaging | 3 | 2021 | 216 | 0.250 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 321 | 0.250 |
Why?
|
| Survival Analysis | 7 | 2021 | 1512 | 0.250 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 151 | 0.250 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 104 | 0.240 |
Why?
|
| Gene Frequency | 2 | 2017 | 662 | 0.240 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 23 | 0.240 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 67 | 0.240 |
Why?
|
| Lymph Nodes | 2 | 2019 | 509 | 0.240 |
Why?
|
| Watchful Waiting | 2 | 2013 | 51 | 0.240 |
Why?
|
| Ferritins | 2 | 2020 | 27 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 318 | 0.230 |
Why?
|
| Brain Neoplasms | 3 | 2014 | 713 | 0.230 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 162 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 99 | 0.230 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.230 |
Why?
|
| Central Nervous System | 1 | 2023 | 144 | 0.220 |
Why?
|
| Transcriptome | 2 | 2016 | 527 | 0.220 |
Why?
|
| Neoplasms | 3 | 2021 | 2687 | 0.220 |
Why?
|
| Cancer Survivors | 1 | 2022 | 74 | 0.210 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 144 | 0.210 |
Why?
|
| Nomograms | 1 | 2020 | 26 | 0.210 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.200 |
Why?
|
| Research Report | 3 | 2021 | 44 | 0.200 |
Why?
|
| Genotype | 2 | 2017 | 1812 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 181 | 0.190 |
Why?
|
| Rituximab | 1 | 2020 | 103 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2022 | 7560 | 0.190 |
Why?
|
| Patient Selection | 2 | 2015 | 661 | 0.190 |
Why?
|
| Incidence | 4 | 2022 | 1540 | 0.190 |
Why?
|
| Mice | 5 | 2019 | 10809 | 0.190 |
Why?
|
| Attitude to Death | 1 | 2019 | 36 | 0.190 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1422 | 0.190 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 34 | 0.190 |
Why?
|
| Mitotic Index | 2 | 2020 | 19 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 25 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2009 | 57 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2019 | 246 | 0.180 |
Why?
|
| Cell Cycle | 2 | 2011 | 496 | 0.180 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 10 | 0.180 |
Why?
|
| Cell Movement | 3 | 2022 | 735 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 158 | 0.180 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1142 | 0.180 |
Why?
|
| Social Stigma | 1 | 2019 | 49 | 0.180 |
Why?
|
| Mitosis | 2 | 2020 | 145 | 0.180 |
Why?
|
| Heterografts | 1 | 2019 | 90 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 254 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2017 | 762 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 136 | 0.170 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 336 | 0.170 |
Why?
|
| Lymphoma | 1 | 2019 | 258 | 0.170 |
Why?
|
| Receptors, KIR | 1 | 2017 | 10 | 0.170 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 223 | 0.170 |
Why?
|
| Ataxia | 1 | 2017 | 32 | 0.170 |
Why?
|
| Palliative Care | 1 | 2019 | 234 | 0.160 |
Why?
|
| Neurologic Examination | 1 | 2017 | 113 | 0.160 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 45 | 0.160 |
Why?
|
| Nurse's Role | 1 | 2017 | 12 | 0.160 |
Why?
|
| Age of Onset | 2 | 2015 | 301 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 243 | 0.160 |
Why?
|
| Biomarkers | 3 | 2020 | 1603 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 221 | 0.150 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 64 | 0.150 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 43 | 0.150 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.150 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 76 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 530 | 0.150 |
Why?
|
| Mutation | 3 | 2016 | 3792 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 125 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2017 | 250 | 0.150 |
Why?
|
| Melphalan | 1 | 2016 | 95 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 961 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2017 | 122 | 0.140 |
Why?
|
| Wernicke Encephalopathy | 1 | 2015 | 4 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1605 | 0.140 |
Why?
|
| Thiamine | 1 | 2015 | 8 | 0.140 |
Why?
|
| Melanoma | 1 | 2019 | 431 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 277 | 0.140 |
Why?
|
| Autografts | 4 | 2017 | 25 | 0.140 |
Why?
|
| Genes, myc | 1 | 2015 | 37 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.140 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 466 | 0.140 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 47 | 0.140 |
Why?
|
| Apoptosis | 2 | 2019 | 1645 | 0.140 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 19 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 349 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 124 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 95 | 0.130 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 291 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 967 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2016 | 334 | 0.130 |
Why?
|
| Karyotyping | 1 | 2014 | 250 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 235 | 0.130 |
Why?
|
| DNA Copy Number Variations | 2 | 2012 | 169 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 166 | 0.130 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 16 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2013 | 99 | 0.130 |
Why?
|
| Cell Survival | 1 | 2016 | 959 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2015 | 154 | 0.130 |
Why?
|
| SEER Program | 1 | 2014 | 180 | 0.130 |
Why?
|
| Animals | 5 | 2019 | 25628 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 24 | 0.130 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 36 | 0.130 |
Why?
|
| Immunomagnetic Separation | 1 | 2013 | 8 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 901 | 0.130 |
Why?
|
| Cell Nucleolus | 1 | 2013 | 23 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2012 | 650 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2012 | 149 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2583 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 44 | 0.120 |
Why?
|
| Camptothecin | 2 | 2013 | 187 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 641 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2018 | 360 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2012 | 752 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 104 | 0.120 |
Why?
|
| Computational Biology | 1 | 2016 | 519 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1742 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2014 | 354 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 109 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 439 | 0.120 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 53 | 0.110 |
Why?
|
| Fenretinide | 1 | 2011 | 2 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1692 | 0.110 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2011 | 33 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 126 | 0.110 |
Why?
|
| Topotecan | 1 | 2011 | 46 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2013 | 289 | 0.110 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2011 | 27 | 0.110 |
Why?
|
| Drug Monitoring | 3 | 2018 | 115 | 0.110 |
Why?
|
| Niacinamide | 1 | 2011 | 116 | 0.110 |
Why?
|
| Loss of Heterozygosity | 3 | 2018 | 84 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 108 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 809 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 381 | 0.100 |
Why?
|
| Radiopharmaceuticals | 3 | 2018 | 159 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 696 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 516 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2008 | 62 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 446 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2013 | 334 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 371 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 254 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2011 | 283 | 0.100 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 67 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 288 | 0.100 |
Why?
|
| Pregnancy Rate | 1 | 2009 | 19 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 336 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1720 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1713 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1189 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 70 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 180 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 119 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 191 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 1034 | 0.080 |
Why?
|
| Consensus | 2 | 2018 | 296 | 0.070 |
Why?
|
| Communication | 2 | 2020 | 401 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 323 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 192 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2018 | 280 | 0.070 |
Why?
|
| Carboplatin | 2 | 2018 | 281 | 0.060 |
Why?
|
| Viral Load | 2 | 2019 | 137 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1018 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2014 | 279 | 0.060 |
Why?
|
| Capsules | 2 | 2013 | 37 | 0.060 |
Why?
|
| Morbidity | 1 | 2022 | 140 | 0.060 |
Why?
|
| Vincristine | 1 | 2021 | 107 | 0.050 |
Why?
|
| Diploidy | 1 | 2020 | 27 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 538 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2010 | 103 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2014 | 692 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2168 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2019 | 16 | 0.050 |
Why?
|
| Alabama | 1 | 2019 | 12 | 0.050 |
Why?
|
| Decision Making | 2 | 2019 | 602 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 21 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2013 | 795 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2003 | 488 | 0.050 |
Why?
|
| Quality of Life | 2 | 2019 | 1392 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 437 | 0.050 |
Why?
|
| Hepatomegaly | 1 | 2018 | 12 | 0.050 |
Why?
|
| Filgrastim | 1 | 2018 | 56 | 0.040 |
Why?
|
| Azepines | 1 | 2018 | 20 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1006 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 106 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 772 | 0.040 |
Why?
|
| Ecosystem | 1 | 2021 | 308 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 922 | 0.040 |
Why?
|
| Pregnancy | 3 | 2009 | 2704 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 37 | 0.040 |
Why?
|
| Thymus Hyperplasia | 1 | 2016 | 3 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 272 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 142 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 124 | 0.040 |
Why?
|
| Ligands | 1 | 2017 | 425 | 0.040 |
Why?
|
| Glutathione | 1 | 2016 | 101 | 0.040 |
Why?
|
| Emotions | 1 | 2019 | 310 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2016 | 300 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2016 | 147 | 0.040 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2440 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 122 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2008 | 319 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 568 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1343 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 347 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Suspensions | 1 | 2013 | 6 | 0.030 |
Why?
|
| Middle Aged | 3 | 2019 | 23961 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 61 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 581 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 291 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 113 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 34 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 350 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 79 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3114 | 0.030 |
Why?
|
| Cytosine | 1 | 2014 | 121 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 299 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 265 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 144 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 147 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 294 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2012 | 41 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 95 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2012 | 110 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 143 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 327 | 0.030 |
Why?
|
| Ploidies | 1 | 2011 | 37 | 0.030 |
Why?
|
| Thymopentin | 1 | 2011 | 2 | 0.030 |
Why?
|
| Tretinoin | 1 | 2012 | 124 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 542 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 20 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2284 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 261 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1939 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2012 | 269 | 0.030 |
Why?
|
| Research | 1 | 2012 | 248 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 342 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 645 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2011 | 163 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2010 | 66 | 0.030 |
Why?
|
| Australia | 1 | 2010 | 93 | 0.030 |
Why?
|
| Logistic Models | 1 | 2014 | 1111 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1931 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 92 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 1126 | 0.030 |
Why?
|
| Age Distribution | 1 | 2010 | 200 | 0.020 |
Why?
|
| North America | 1 | 2010 | 174 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 298 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 17475 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 300 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 679 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 497 | 0.020 |
Why?
|
| Gravidity | 1 | 2009 | 6 | 0.020 |
Why?
|
| Sex Education | 1 | 2009 | 9 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 885 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2009 | 42 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 60 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2009 | 29 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6214 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 27 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 879 | 0.020 |
Why?
|
| Birth Weight | 1 | 2008 | 141 | 0.020 |
Why?
|
| Body Height | 1 | 2008 | 97 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 54 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 2287 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1507 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2007 | 87 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 896 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 450 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 226 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 163 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1340 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 241 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 491 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2158 | 0.020 |
Why?
|
| Hepatitis A Vaccines | 1 | 2003 | 3 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 1 | 2003 | 3 | 0.020 |
Why?
|
| Mumps virus | 1 | 2003 | 3 | 0.020 |
Why?
|
| Tetanus Toxoid | 1 | 2003 | 10 | 0.020 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2003 | 5 | 0.020 |
Why?
|
| Azithromycin | 1 | 2003 | 13 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 72 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2003 | 92 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 3147 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 948 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 675 | 0.010 |
Why?
|